Insulet Celebrates Milestone of 100,000 Customers Actively Using the Omnipod® System
November 16 2016 - 6:00AM
Business Wire
During National Diabetes Awareness Month,
Insulet honors Omnipod users and reinforces commitment to help make
living with diabetes easier
Insulet Corporation (NASDAQ: PODD) (Insulet or the
Company), the leader in tubeless insulin pump technology with its
Omnipod® Insulin Management System (Omnipod System), today
announced it has reached a milestone of 100,000 global users
enjoying the quality of life benefits of the Omnipod System. The
Company is celebrating this significant milestone during National
Diabetes Awareness Month and is conducting a number of events to
drive further awareness around diabetes and Omnipod.
The Food and Drug Administration (FDA) cleared the first
tubeless insulin delivery system, the Omnipod System, in 2005. The
Omnipod System provides users – referred to as “Podders” – with a
tubeless, waterproof patch-pump technology that offers significant
quality of life benefits. This includes a differentiated design
that provides 72 hours of non-stop, discreet insulin delivery and
eliminates the need for multiple daily injections. The Omnipod
System’s positive impact on quality of life and user experience has
been further validated in a recent study of more than ~1,200 users
published in Diabetes Technology & Therapeutics1. The majority
of Podders reported improvements in their perceived control over
their diabetes and hypoglycemic safety, among other benefits, since
starting use of the Omnipod System.
Gwynn Harris is the mother of seven-year-old Podder, Anna. She’s
thrilled Anna has been recognized as one of the group of Podders
who helped Insulet achieve the milestone of 100,000 users worldwide
and feels fortunate to be part of such a supportive community.
“As a parent of a child with type 1 diabetes, I can testify that
using the Omnipod System is truly a game-changer for us – it
significantly improves our lives for the better,” said Gwynn. “The
Omnipod helps reduce the impact diabetes has on Anna’s life. She is
able to follow her passions and pursue her hobbies, including
skiing, swimming and playing tennis. The Omnipod technology keeps
us from interrupting Anna through these daily activities as we help
her manage her condition. We all feel like we have our freedom
back.”
Podder Stephanie Tennis is another recent Omnipod user, and one
of the 100,000 Podders worldwide who appreciates the many quality
of life benefits offered by the Omnipod System. As a driver for
multiple transportation network companies in Nashville, she enjoys
educating her passengers about the benefits of the Omnipod System
and the freedom it offers people living with diabetes.
“The Omnipod System allows me to be more spontaneous,” Tennis
said. “I have the flexibility to eat what I want, when I want –
which I never had while using multiple daily injections. With my
Pod, it’s much easier to manage my diabetes. I can say ‘yes’ to
grabbing coffee with a friend on a whim without too much
thought…that seems small, but it’s a big deal when you’re living
with this condition every day.”
“We have always had a strong commitment to our Podder
community,” says Patrick Sullivan, Chairman and Chief Executive
Officer. “The stories shared by our community of 100,000 global
Podders and counting not only help to increase awareness about the
benefits of Omnipod, but also inspire the Insulet team as we
continue to innovate on this unique platform. We are proud to bring
our differentiated technology to people across the world to give
people with diabetes a sense of freedom and control.”
1 Polonsky WH et al. Diabetes Technol Ther. 2016;18:664-670.
About the Omnipod Insulin Management System:
The Omnipod Insulin Management System is an innovative
continuous insulin delivery system that provides all the proven
benefits of continuous subcutaneous insulin infusion (CSII) therapy
in a way no conventional insulin pump can. The Omnipod System's
innovative design and features allows people living with diabetes
to live their life—and manage their diabetes—with unprecedented
freedom, comfort, convenience, and ease. The Omnipod System
consists of two components: (i) a Pod that stores and delivers
insulin; and (ii) a Personal Diabetes Manager (PDM) that wirelessly
programs the user's personalized insulin delivery, calculates
suggested doses and insulin on board, and has a convenient,
built-in blood glucose meter. The small, light-weight Pod can be
worn in multiple locations, including the abdomen, hip, back of
upper arm, upper thigh or lower back and, because it is waterproof
(IPX8), there is no need to remove when showering, swimming or
performing other activities. This means that Omnipod can provide up
to three days of non-stop insulin delivery, without the need to
disconnect a tube set or manually inject insulin. The Pod and
PDM communicate wirelessly to offer precise, personalized and
continuous insulin delivery with customizable basal and bolus
delivery options, as well as important safety checks. The Pod's
auto-cannula insertion is quick, simple, and virtually pain-free.
Users never have to handle a needle. The user simply pushes a
button on the PDM and the Pod's automated insertion system inserts
the cannula beneath the skin and begins delivering insulin
according to the user's programmed basal rate.
The Omnipod System is the world's first commercially available
tubeless insulin delivery system that allows users to live
untethered by tubing and without the stress and anxiety of multiple
daily injections. By breaking down the barriers to insulin pump
therapy, the Omnipod System offers freedom for users to live life
on their own terms and with the ease of use they deserve.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical
device company dedicated to making the lives of people with
diabetes easier. Through its Omnipod Insulin Management
System, Insulet seeks to expand the use of insulin pump
therapy among people with insulin-dependent diabetes. The Omnipod
is a revolutionary and easy-to-use tubeless insulin pump that
features just two parts and a fully-automated cannula
insertion. Insulet's Delivery Systems business also
partners with global pharmaceutical and biotechnology companies to
tailor the Omnipod technology platform for the delivery of
subcutaneous drugs across multiple therapeutic areas. Founded in
2000, Insulet Corporation is based in Billerica,
Massachusetts. For more information, please
visit: http://www.myomnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations,
intentions, beliefs or strategies regarding the future. These
forward-looking statements are based on its current expectations
and beliefs concerning future developments and their potential
effects on Insulet. There can be no assurance that future
developments affecting Insulet will be those that it has
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or
other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties
described in its Annual Report on Form 10-K, which was filed with
the Securities and Exchange Commission on February
29, 2016 in the section entitled "Risk Factors," and in its
other filings from time to time with the Securities and
Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should any of its assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking
statements. Insulet undertakes no obligation to publicly
update or revise any forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161116005152/en/
Investor Relations and Media Contact:Insulet
CorporationDeborah R. Gordon, 978-600-7717Vice President, Investor
Relations and Corporate Communicationsdgordon@insulet.com
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Apr 2023 to Apr 2024